Dec 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, so called biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. After receiving positive pre- clinical trial results for QPG-1029, QuiaPEG today announces that it has signed a Material Transfer Agreement (MTA) with an Asian pharmaceutical company regarding the QPG-1029 drug project (peg-liraglutid), which has blockbuster1 potential in the indications diabetes and overweight.

Download press release (PDF)
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message